NASDAQ: IPHA · Biotechnology
Over the past week, Innate Pharma (IPHA) racked up about 22 mentions across Reddit, X and news, and the read is an Adanos Sell. The crowd averages 34% bullish but is deeply split: News runs 50% bullish while X sits at just 17%. Wall Street is more constructive, with 3 of 4 analysts rating IPHA a buy.
There is little buzz around IPHA this week and some agreement on direction, which is why it reads as a Sell.
Wall Street’s 75% buy share sits next to a crowd that ranges from X at 17% to News at 50%. No other tracker puts the two side by side.
Across 4 analysts the consensus is a Strong Buy: 3 buy calls against 0 sell, with an average 12-month price target of $6.50.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits just below the neutral line, momentum is improving and the 2 sources disagree sharply, so the read is a Sell.
Analysts sit 41 points above the crowd average of 34%, the professionals are more constructive than retail. The split is inside the crowd: News reads 50% bullish while X sits at 17%, a 33-point spread that single-source trackers miss.
Over the 30-day window, Innate Pharma (IPHA) buzz held subdued around 34.0 while the price drifted up 24.6% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 384K shares. Updated Aug 15, 2026. Over the last 7 trading days, IPHA gained 22.1%. Buzz activity in the recent week averaged 27.6 and was variable, swinging between 17.5 and 38.7. Recent volume is running above the 30-day average, suggesting heightened trading interest. Daily crowd sentiment leaned bullish on 2 of the 6 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Reddit data for this stock this week.
No Polymarket data for this stock this week.
Query sentiment for IPHA and 2000+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live IPHA sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Aug 15, 2026.
| Adanos signal | Sell |
|---|---|
| Analyst consensus | Strong Buy (3 / 1 / 0) |
| Crowd bullish (7d) | 34% |
| Avg price target | $6.50 |
| Most bullish source | News, 50% |
| Most bearish source | X, 17% |
| Sentiment spread | 33 pts |
| Mentions (7d) | 22 |
| Market cap | $204.7M |
| EPS · Beta | -$0.63 · 0.9 |
| Revenue (TTM) | $9M · 0% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from X and News sources, Innate Pharma (IPHA) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 34% bullish across 2 active sources. Those sources contribute 22 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
The crowd reads bearish on Innate Pharma (IPHA), averaging 34% bullish across 2 tracked sources over the last 7 days. The two ends of the range are News at 50% bullish and X at 17%, a 33-point spread. On the professional side, 3 of 4 analysts rate IPHA a buy.
Of the 4 analysts covering Innate Pharma (IPHA), 3 rate it a buy, 1 a hold and 0 a sell, for a strong buy consensus. The average price target is $6.50. That puts the street ahead of the crowd, which averages 34% bullish.
Innate Pharma (IPHA)'s cross-source average is bearish at 34% bullish. Source readings are split: 1 source leans bearish and 1 source sits at 50% bullish. News reads 50% bullish and x coverage is the most negative at 17% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
The cross-source average is bearish for Innate Pharma (IPHA) at 34% bullish. Source readings are split: 1 source leans bearish and 1 source sits at 50% bullish. The most bearish reading is x at 17% bullish. 3-day activity momentum is rising across X and News. The sell signal carries 93/100 conviction.
News is the dominant discussion channel with 16 mentions (73% of total volume). X contributes 6 mentions. The cross-source average is bearish at 34% bullish, while x and news show rising 3-day activity. Source readings are split: 1 source leans bearish and 1 source sits at 50% bullish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. IPHA's sell signal at 93/100 conviction reflects a bearish cross-source average at 34% bullish. Source readings are split: 1 source leans bearish and 1 source sits at 50% bullish. It is a research shortcut, not financial advice.
The IPHA sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Sell signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key